The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Journal club · continued

Second pass at: Journal club: STEP 4 and what a withdrawal design can prove posts 31–60

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

IN
i.norgaardTL219 Jun 2025#31

Post #28 is the version of this I will quote in future. One addition.

I would rather this thread reach "we do not know" about STEP 4 than reach a confident answer that nobody can support when asked.

15 likes 13mo
IT
impurity_tableTL3Analytical chemist22 Jun 2025#32
d.bakker, post #26: The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. Reading it back, the second half matters more than the first. Go to post

Two claims get bundled together under STEP 4 and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.

Almost every disagreement in threads like this one dissolves once you say which of the two you are making.

30 likes in reply to #26 13mo
NL
n.laurentTL225 Jun 2025#33

Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.

Marking that as an opinion rather than a finding.

0 likes 13mo
CR
compounding_ruthTL4Pharmacist28 Jun 2025#34

The most useful thing anyone has posted about STEP 4 in this category was a table of what had been measured and by whom. That is what I would want again.

3 likes 13mo
VS
v.sjobergTL230 Jun 2025#35
p.marchetti, post #25: Worth stating the null on STEP 4 before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one. Go to post

Where the STEP 4 reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.

10 likes in reply to #25 13mo
TV
t.vasquezTL4 Moderator3 Jul 2025 · edited#36
n.laurent, post #33: Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows. Marking that as an opinion rather than a finding. Go to post

Useful. I have added it to my own notes with the date on it.

22 likes in reply to #33 13mo
MR
m.rasmussenTL26 Jul 2025#37
ZO
z.onwukaTL28 Jul 2025#38

Answering the question post #34 raises rather than the one it answers.

I think the STEP 4 question is answerable and has not been answered, which is a more optimistic position than most of this thread.

1 like 13mo
NP
n.petrovTL211 Jul 2025#39

STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially larger than anything previously achieved pharmacologically.

That is the version I use. It may not be the version that is correct.

29 likes 13mo
BN
b.nilsenTL214 Jul 2025#40

Coming back to post #38, because the follow-up matters more than the original answer.

STEP 4 would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.

0 likes 12mo
G
GSwinburneTL1Member16 Jul 2025#41

I read post #39 twice before replying, because I had assumed the opposite.

Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.

21 likes 12mo
MO
m.oyelaranTL219 Jul 2025#42

Distinguishing three things in the STEP 4 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.

9 likes 12mo
CI
citation_indexTL221 Jul 2025#43
AK
a.kravchenkoTL224 Jul 2025#44
s.chowdhury, post #19: This follows post #17 rather than contradicting it. Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later. Go to post

Adding thanks rather than a view. I do not have a view worth the space.

15 likes in reply to #19 12mo
B
BirkelandTL3Regular26 Jul 2025 · edited#45

Everything in post #42 holds. The case it does not cover is the one I have.

Trying to state the STEP 4 position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.

3 likes 12mo
VR
v.rautioTL229 Jul 2025#46

Narrowing post #45, because the general version has more than one answer.

A conflict-of-interest statement is worth reading aloud and is worth very little as a predictor. Design quality is what to spend the session on.

0 likes 12mo
CT
cannula_traceTL3Regular1 Aug 2025#47

An honest declaration on STEP 4: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

22 likes 12mo
GA
g.amankwahTL23 Aug 2025#48
lyophil_margin, post #15: The useful distinction on STEP 4 is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars. Go to post

Having read the whole STEP 4 thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.

10 likes in reply to #15 12mo
O
OTeixeiraTL3Regular6 Aug 2025#49
lyophil_margin, post #15: The useful distinction on STEP 4 is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars. Go to post

STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially larger than anything previously achieved pharmacologically.

If this contradicts something upthread, the upthread version may well be the better one.

1 like in reply to #15 12mo
SO
s.oyelaranTL28 Aug 2025#50
FP
forest_plotTL3Evidence synthesis11 Aug 2025#51

Building on post #49 rather than restating it.

An hour is enough for one paper read properly and not enough for two read partly. The temptation is always to add the second.

19 likes 12mo
ES
e.steinerTL213 Aug 2025#52

Post #48 put the caveat in the right place and I want to underline it.

Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.

0 likes 11mo
QZ
q.zhao_qaTL3Quality assurance15 Aug 2025#53
v.sjoberg, post #35: Where the STEP 4 reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for. Go to post

The question underneath STEP 4 is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

2 likes in reply to #35 11mo
IL
i.lehtinenTL218 Aug 2025 · edited#54

I would put moderate confidence on the mainstream reading of STEP 4 and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.

8 likes 11mo
PI
p.iyer_pharmdTL3Pharmacist20 Aug 2025#55

The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.

Worth one more sentence than it usually gets.

26 likes 11mo
HI
h.iyerTL223 Aug 2025#56
s.chowdhury, post #19: This follows post #17 rather than contradicting it. Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later. Go to post

Post #52 and I disagree about the size of the effect, not about the direction.

Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?

0 likes in reply to #19 11mo
BI
blank_injectionTL2Analytical chemist25 Aug 2025#57
impurity_table, post #32: Two claims get bundled together under STEP 4 and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not. Almost every disagreement in threads like this one dissolves once you say which of the two you are making. Go to post

Bookmarking this. I will come back when I have something worth adding.

4 likes in reply to #32 11mo
NV
n.villalobosTL228 Aug 2025#58

Where I have landed on STEP 4, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.

12 likes 11mo
ER
eire_readerTL2Regional · IE30 Aug 2025 · edited#59

What I would want before treating STEP 4 as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.

0 likes 11mo
ZS
z.szaboTL21 Sep 2025#60